Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
INCY
INCY
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
INCY News
Incyte Grants Equity Inducement Awards to New CFO Suketu Upadhyay
3d ago
Newsfilter
NIKTIMVO Approved in Australia for Chronic Graft-Versus-Host Disease Treatment
May 03 2026
Newsfilter
Incyte Receives FDA Approval for Jakafi XR
May 02 2026
NASDAQ.COM
FDA Approves Jakafi XR for Myelofibrosis and GVHD Treatment
May 01 2026
Newsfilter
Incyte Reports Strong Q1 2026 Earnings with Strategic Growth Plans
Apr 28 2026
seekingalpha
Incyte Q1 Earnings Exceed Expectations with Strong Revenue Growth
Apr 28 2026
seekingalpha
Incyte Q1 Earnings Preview and Estimates
Apr 27 2026
seekingalpha
Minjuvi® Approved in Australia for Relapsed Follicular Lymphoma Treatment
Apr 23 2026
Newsfilter
Palvella Appoints New Senior Vice President of Sales
Apr 07 2026
Globenewswire
Palvella Appoints New Senior Vice President of Sales
Apr 07 2026
Newsfilter
Trump May Announce New Drug Tariffs Soon
Apr 02 2026
seekingalpha
Adagene and Incyte Collaborate on Clinical Study for MSS CRC
Apr 02 2026
Globenewswire
Povorcitinib Shows Significant Efficacy in Hidradenitis Suppurativa Treatment
Mar 28 2026
Newsfilter
Povorcitinib Shows Significant Efficacy in HS Treatment at 54 Weeks
Mar 28 2026
Yahoo Finance
INCYTE: PHASE 3 RESULTS FROM STOP-HS TRIAL DEMONSTRATE SUSTAINED CLINICAL EFFICACY OF POVORCITINIB THROUGH WEEK 54 IN MODERATE TO SEVERE HS PATIENTS
Mar 28 2026
moomoo
Incyte Unveils Latest Data on Povorcitinib at AAD 2026
Mar 20 2026
Newsfilter
Show More News
